Spyre Therapeutics, INC Form 4 insider transactions

Heidy King-Jones, See Remarks of Spyre Therapeutics, Inc., sold 28,933 shares of common stock on October 1, 2026.

Cameron Turtle, Chief Executive Officer and a Director of Spyre Therapeutics, Inc., sold 15,000 shares of common stock on October 1, 2026.

Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., sold 25,000 shares of common stock on September 30, 2026.

Heidy King-Jones, See Remarks of Spyre Therapeutics, Inc., sold 28,399 shares of common stock on September 1, 2026.

Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., sold 25,732 shares of common stock on September 1, 2026.

Cameron Turtle, Chief Executive Officer and a Director of Spyre Therapeutics, Inc., sold 15,000 shares of common stock on September 1, 2026.

Jeffrey W. Albers, a Director of Spyre Therapeutics, Inc., sold 23,000 shares of common stock on August 7, 2026.

Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., sold 7,500 shares of common stock on August 3, 2026.

Cameron Turtle, Chief Executive Officer and a Director of Spyre Therapeutics, Inc., sold 15,000 shares of common stock on August 3, 2026.

Spyre Therapeutics' Chief Financial Officer, Scott L. Burrows, executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.

Sloan Sheldon, Chief Medical Officer of Spyre Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a Rule 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle has sold a significant number of company shares through a pre-arranged trading plan.

Spyre Therapeutics, Inc. CFO Scott L. Burrows reports transactions involving common stock and stock options.

Fairmount Funds Management LLC and its affiliates reported the conversion of Series B Preferred Stock into common stock, alongside a sale of common stock.

Director Michael Henderson reported a transaction involving 20,000 shares of Spyre Therapeutics, Inc. common stock on June 22, 2026, executed under a Rule 10b5-1 trading plan.

Chief Medical Officer Sheldon Sloan exercised options and sold 8,333 shares of Spyre Therapeutics at $75.00 per share under a pre-arranged trading plan.

Chief Executive Officer Cameron Turtle sold 15,000 shares of Spyre Therapeutics as part of a pre-arranged trading plan while maintaining a substantial equity position.

Spyre Therapeutics CFO Scott L. Burrows exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Fairmount Funds Management's Tomas Kiselak was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of his board service.

Director Jeffrey W. Albers was granted 8,026 stock options in Spyre Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Director Michael Thomas Henderson was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Director Laurie Stelzer was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Mark C. McKenna was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Director Sandra Milligan was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Director Michael Thomas Henderson sold 80,000 shares of Spyre Therapeutics, Inc. on May 8, 2026, as part of a pre-arranged trading plan.

Spyre Therapeutics Chief Financial Officer Scott L. Burrows exercised options and sold 12,500 shares of common stock as part of a pre-arranged trading plan.

Chief Medical Officer Sheldon Sloan exercised options and sold 78,333 shares of Spyre Therapeutics under a pre-arranged trading plan.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle sold company stock valued at approximately $607,000 through a pre-arranged trading plan.

Spyre Therapeutics, Inc. reports that Chief Medical Officer Sheldon Sloan sold 7,958 shares of common stock on April 1, 2026, as part of a pre-arranged 10b5-1 trading plan.